Basic Trial Information
|Phase II||Treatment||Closed||18 and over||NCI, Other||RTOG 0937|
CDR0000663959, NCI-2011-02008, NCT01055197
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. This may be an effective treatment for extensive stage small cell lung cancer.
PURPOSE: This randomized phase II trial is comparing how well radiation therapy to the brain works when given with or without radiation therapy to other areas of the body in treating patients with extensive stage small cell lung cancer.
Further Study Information
- To compare the 1-year overall median survival rate in patients with extensive stage small cell lung cancer treated with prophylactic cranial irradiation with vs without consolidative extracranial radiotherapy following platinum-based chemotherapy.
- To compare treatment-related adverse events in these patients.
- To evaluate patterns of failure in these patients.
- To compare the time to first failure in these patients.
- To evaluate the percentage of the planned radiotherapy dose given to each site.
OUTLINE: This is a multicenter study. Patients are stratified according to response to prior treatment (complete response vs partial response) and number of metastatic lesions (1 vs 2-3). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo prophylactic cranial irradiation 5 days per week for 2 weeks.
- Arm II: Patients undergo prophylactic cranial irradiation as in arm I. Patients also undergo consolidative extracranial radiotherapy to locoregional and residual metastatic disease 5 days per week for 2-3 weeks.
After completion of study treatment, patients are followed up at 2 weeks; at 1, 2, 6, 9, and 12 months; every 6 months for 2 years; and then annually thereafter.
- Histologically or cytologically confirmed extensive stage small cell lung cancer (SCLC) diagnosed within the past 6 months*
- Has 1-4 extracranial metastatic lesions NOTE: *Diagnosis made before treatment with chemotherapy
- Has completed 4-6 courses of platinum-based chemotherapy within the past 8 weeks AND meets the following criteria:
- Radiographic partial or complete response to chemotherapy in ≥ 1 site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria (if radiotherapy has been delivered to primary disease with chemotherapy, there must be complete or partial response in ≥ 1 of the sites that has not been treated with radiotherapy)
- No progression in any site
- No limited stage SCLC, even if disease progressed
- No brain or central nervous system (CNS) metastases
- Zubrod performance status 0-2
- Absolute neutrophil count (ANC) ≥ 1,000/mm^3
- Hemoglobin ≥ 8.0 g/dL (the use of transfusion or other intervention is allowed)
- Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal (ULN) (for patients who will receive radiotherapy to the liver)
- Serum bilirubin < 1.5 times ULN (for patients who will receive radiotherapy to the liver)
- Serum creatinine < 1.5 times ULN (for patients who will receive radiotherapy to the kidneys)
- Fertile patients must use effective contraception
- No severe, active co-morbidity, defined as any of the following:
- Acute bacterial or fungal infection requiring IV antibiotics at the time of study registration
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of study registration
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior chemotherapy (i.e., toxicities ≤ grade 1 [except for neuropathy and alopecia])
- Thoracic radiotherapy administered concurrently with or before chemotherapy for the current diagnosis allowed (these patients will not receive mediastinal radiotherapy per protocol)
- No prior radiotherapy to the region of this cancer that would result in overlap of radiotherapy fields
- No concurrent chemotherapy
Trial Lead Organizations/Sponsors
Radiation Therapy Oncology Group
- National Cancer Institute
- NRG Oncology
Elizabeth M. Gore, Principal Investigator
Alexander Sun, MD, Principal Investigator
Hawaii Medical Center - East
Paul A. DeMare
Queen's Cancer Institute at Queen's Medical Center
Paul A. DeMare
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Elizabeth M. Gore
Regional Cancer Center at Oconomowoc Memorial Hospital
Wingate F. Clapper
Waukesha Memorial Hospital Regional Cancer Center
Wingate F. Clapper
Cross Cancer Institute at University of Alberta
McGill Cancer Centre at McGill University
Elizabeth M. Gore
Link to the current ClinicalTrials.gov record.
NLM Identifier NCT01055197
ClinicalTrials.gov processed this data on May 04, 2015
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.